Market capitalization | $23.54m |
Enterprise Value | $25.06m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 10.37 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-23.68m |
Cash position | $9.51m |
EPS (TTM) EPS | $-9.87 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
3 Analysts have issued a Polypid Ltd forecast:
3 Analysts have issued a Polypid Ltd forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -24 -24 |
40%
40%
|
|
Depreciation and Amortization | 1.82 1.82 |
6%
6%
|
|
Stock Compensation | 3.39 3.39 |
21%
21%
|
|
Operating Cash Flow | -17 -17 |
50%
50%
|
|
Investments | 0.20 0.20 |
89%
89%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -17 -17 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Head office | Israel |
CEO | Dikla Akselbrad |
Employees | 62 |
Founded | 2008 |
Website | www.polypid.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.